Idioma:

ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression

Fritzsche, Florian R ; Wassermann, Kirsten ; Jung, Monika ; Tölle, Angelika ; Kristiansen, Ilka ; Lein, Michael ; Johannsen, Manfred ; Dietel, Manfred ; Jung, Klaus ; Kristiansen, Glen

BMC cancer, 2008-06, Vol.8 (1), p.179-179, Article 179 [Revista revisada por pares]

England: BioMed Central Ltd

Texto completo disponible

Citas Citado por

Acciones

Título:
ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression
Autor: Fritzsche, Florian R ; Wassermann, Kirsten ; Jung, Monika ; Tölle, Angelika ; Kristiansen, Ilka ; Lein, Michael ; Johannsen, Manfred ; Dietel, Manfred ; Jung, Klaus ; Kristiansen, Glen
Materias: ADAM Proteins - biosynthesis ; ADAM Proteins - genetics ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Renal cell ; Carcinoma, Renal Cell - enzymology ; Carcinoma, Renal Cell - genetics ; Carcinoma, Renal Cell - pathology ; Disease Progression ; Disease-Free Survival ; Female ; Gene expression ; Gene Expression Regulation, Neoplastic ; Genetic aspects ; Humans ; Immunohistochemistry ; Kidney Neoplasms - enzymology ; Kidney Neoplasms - genetics ; Kidney Neoplasms - pathology ; Male ; Membrane Proteins - biosynthesis ; Membrane Proteins - genetics ; Middle Aged ; Physiological aspects ; Proteases ; Reverse Transcriptase Polymerase Chain Reaction ; RNA, Messenger - biosynthesis ; RNA, Messenger - genetics ; RNA, Neoplasm - genetics ; RNA, Neoplasm - metabolism ; Up-Regulation
Es parte de: BMC cancer, 2008-06, Vol.8 (1), p.179-179, Article 179
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
Descripción: A Disintegrin And Metalloprotease (ADAM) 9 has been implicated in tumour progression of various solid tumours, however, little is known about its role in renal cell carcinoma. We evaluated the expression of ADAM9 on protein and transcript level in a clinico-pathologically characterized renal cell cancer cohort. 108 renal cancer cases were immunostained for ADAM9 on a tissue-micro-array. For 30 additional cases, ADAM9 mRNA of microdissected tumour and normal tissue was analyzed via quantitative RT-PCR. SPSS 14.0 was used to apply crosstables (Fisher's exact test and chi2-test), correlations and univariate as well as multivariate survival analyses. ADAM9 was significantly up-regulated in renal cancer in comparison to the adjacent normal tissue on mRNA level. On protein level, ADAM9 was significantly associated with higher tumour grade, positive nodal status and distant metastasis. Furthermore, ADAM9 protein expression was significantly associated with shortened patient survival in the univariate analysis. ADAM9 is strongly expressed in a large proportion of renal cell cancers, concordant with findings in other tumour entities. Additionally, ADAM9 expression is significantly associated with markers of unfavourable prognosis. Whether the demonstrated prognostic value of ADAM9 is independent from other tumour parameters will have to be verified in larger study cohorts.
Editor: England: BioMed Central Ltd
Idioma: Inglés

Enlaces

View this record in MEDLINE/PubMed

Volver a la lista de resultados

Anterior Resultado 4 Siguiente Ir a la siguiente página

Realización: Logos de Redes Sociales:

ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression

Fritzsche, Florian R ; Wassermann, Kirsten ; Jung, Monika ; Tölle, Angelika ; Kristiansen, Ilka ; Lein, Michael ; Johannsen, Manfred ; Dietel, Manfred ; Jung, Klaus ; Kristiansen, Glen

England: BioMed Central Ltd

Buscando en bases de datos remotas, por favor espere